Physician profile
Daniel B Jones
NPI 1366411506
$1,738.58
in general payments reported to CMS, 2019-2025
24 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $88.03 · 2021: $96.90 · 2022: $173 · 2023: $778 · 2024: $138 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.40 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $475.93 | 2023 | Tolak |
| Abbvie INC. | $261.88 | 2019-2025 | |
| Pfizer INC. | $137.39 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $109.02 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $107.94 | 2021-2025 | Dupixent |
| Amgen INC. | $101.30 | 2020-2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.02 | 2019-2025 | Jublia, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $51.02 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $48.02 | 2019-2022 | |
| Janssen Biotech, INC. | $47.28 | 2019-2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $47.10 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $39.74 | 2023 | Vtama |
| Ucb, INC. | $39.38 | 2019-2023 | Cimzia |
| Genzyme Corporation | $36.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.73 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.05 | 2022-2023 | Taltz |
| Biofrontera INC. | $18.05 | 2021 | |
| Fresenius Kabi USA, LLC | $16.41 | 2023 | Idacio |
| Botanix Sb INC | $16.14 | 2025 | Sofdra |
| Taro Pharmaceuticals USA, INC. | $15.40 | 2019 | |
| Celgene Corporation | $14.65 | 2019 | |
| Galderma Laboratories, L.P. | $14.19 | 2024 | |
| Mayne Pharma Commercial LLC | $11.20 | 2019 | |
| Merck Sharp & Dohme LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.